Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
about
Quantification of HER family receptors in breast cancerNeoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ hybridizationThe role of the pathologist in the decision-making process.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerQuantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approachWSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigaQuantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerTechnical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.The Globalization of Cooperative Groups.HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerPathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.HER2 expression status in diverse cancers: review of results from 37,992 patients.PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.Levey-Jennings Analysis Uncovers Unsuspected Causes of Immunohistochemistry Stain Variability.HER2-positive breast cancer is lost in translation: time for patient-centered research.The assessment of HER2 status in breast cancer: the past, the present, and the future.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.FISH in triple-negative breast cancer: a possible strategy for the future?Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
P2860
Q27015506-B6038B9D-01D1-4A47-95E3-9FB5D0DB303BQ33442144-90B12E59-F2FD-4F8C-AA35-9743B3365DF3Q33688726-F2F5D74D-549E-4952-955A-3A707B6F25BBQ33692695-30749132-B055-436E-9A6A-090C3D702731Q33697907-3859492C-7FC6-4BC0-B271-8F5D4784A1CEQ33862786-A8169050-FAC0-4217-B68F-A9B4380D55F5Q34511787-F61C2787-78D9-438C-93C1-DF8CD272A10CQ34717908-3859BA88-B342-4A81-B24A-AB36D2950E01Q34956588-354DD442-4F3D-4CE6-B0F1-BA1DD8BE9BBBQ35343184-4FE5D4B4-6BE3-4B63-873D-8C3A09698BE6Q35983341-C7F452CE-BA55-476E-AEDA-B7A5FEF0F5FDQ36009610-4E3C28EE-A216-4494-A57D-FDCF8F285113Q36064908-FB9AC2B3-B66D-454C-8D6D-62158A5513F2Q36070547-2CFD4858-48BF-4195-866C-5B9C1F060B4BQ36119749-648B173F-FE11-4E9C-B302-6F505B26CBEDQ36849324-62654E80-5482-4DF3-BBDA-2F73EDA91DC9Q36907273-1C7A94F1-F7BC-4196-A55F-0B0CFA78D613Q38272730-8D2C343F-5C89-41B5-9F39-7B96FF03E3A5Q38326102-0741F116-C8C4-49C4-8B0E-ADD2A7EED3EEQ38364900-5C1DA92B-146C-4F37-9CE2-2921F529A75DQ38462629-9CB1C42B-1751-4B4B-A5DA-E4F242F83484Q38607771-C73045AB-802D-4B8A-8296-DBDA87F13D65Q38648765-6401AB89-C864-494F-B2FD-16E827DF1B68Q38802932-39346B60-0E9B-47D3-9733-51CE76160DB3Q39187437-DE1F2885-E0A1-4DE5-A920-3D537A03B6C5Q40386096-51C62EBE-0861-4B1C-9A87-F08D6D9E8EB4Q42377436-9D040CFC-FDD8-41C4-A983-58229F7BA2F4Q44983962-D9697E01-EEB4-4CDC-8BA3-85139AF010B3Q47981933-0B86F95A-94ED-4AA0-B67B-AC382DE7B1C0Q48088758-6424F4A4-95AE-4117-AC4B-5547259DF987Q48550447-98D66034-D3F4-48D9-8830-67738EAD0153Q49545664-80458C12-FA88-4E82-BBD7-8416E2491C44Q50893707-57B5AD39-8F98-443E-A589-9482E1E223E1Q50899665-A1E88AC6-B6D0-4660-AAC2-2F5504A5BE04
P2860
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@ast
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@en
type
label
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@ast
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@en
prefLabel
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@ast
Immunohistochemistry and fluor ...... 31, BCIRG 006, and BCIRG 005).
@en
P2093
P2860
P1476
Immunohistochemistry and fluor ...... 831, BCIRG 006, and BCIRG 005)
@en
P2093
Anne E Wiktor
Beiyun Chen
Dennis J Slamon
Edith A Perez
Howard M Stern
Ivonne Villalobos
Joanne Zujewski
Marc Buyse
Melanie Finnigan
Michael F Press
P2860
P2888
P304
P356
10.1007/S10549-013-2444-Y
P407
P577
2013-02-19T00:00:00Z